Shopping Cart 0
Cart Subtotal
USD 0

H. Lundbeck AS (LUN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of the central nervous system (CNS) diseases including psychiatric and neurological disorders. Its products are indicated for the treatment of diseases such as Alzheimer's disease, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington's disease, among others. The company operates production facilities in Denmark, France, Italy and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies and hospitals in Europe, the US and other countries. Lundbeck is headquartered in Valby, Denmark.

H. Lundbeck AS (LUN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

H. Lundbeck AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For USD 27 Million 15

Venture Financing 17

Naurex Raises USD80 Million in Series C Venture Financing 17

Naurex Raises USD 25 Million In Venture Financing 19

Naurex Raises USD 38 Million In Series B Financing 21

Partnerships 23

Confo Therapeutics Enters into Agreement with H. Lundbeck 23

Cerveau Technologies Enters into Research Agreement with Lundbeck 24

H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 25

Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 26

H. Lundbeck Enters into Agreement with IBM Watson Health 27

Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 28

Ossianix Expands and Extends Research Agreement with Lundbeck 29

Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 30

Ossianix Enters Into Co-Development Agreement With Lundbeck 31

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33

Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 34

Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 35

ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 36

Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer's Disease 37

Licensing Agreements 38

MindImmune Therapeutics Enters into Licensing Agreement with Lundbeck 38

Lundbeck Enters into Licensing Agreement with Vanderbilt University 39

Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 40

Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 41

H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 42

Equity Offering 43

H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 43

H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 44

Chelsea Therapeutics Completes Public Offering Of Shares For USD 23 Million 45

Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of USD 100 Million 46

Chelsea Therapeutics Completes Public Offering Of Common Stock For USD 24 Million 47

Asset Transactions 49

Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For USD 100 Million 49

Acquisition 51

Lundbeck Acquires Prexton Therapeutics 51

H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 52

Lundbeck Acquires 4.6% Stake In Biotie Therapies For USD 13 Million 54

H. Lundbeck AS-Key Competitors 55

H. Lundbeck AS-Key Employees 56

H. Lundbeck AS-Locations And Subsidiaries 57

Head Office 57

Other Locations & Subsidiaries 57

Recent Developments 61

Financial Announcements 61

Nov 07, 2018: Lundbeck realized 12% growth in revenue and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised 61

Aug 08, 2018: Lundbeck realized 14% growth in revenue (local currencies) and 83% growth in EPS 62

May 08, 2018: Lundbeck realized 14% growth in revenue (local currency) and 103% growth in EPS 76

Feb 07, 2018: Lundbeck delivers its best financial results following 10% revenue growth and 117% growth in net profit 77

Nov 08, 2017: Lundbeck increased operating profit (EBIT) with 126% and EPS by 182% in the first nine months of 2017 78

Aug 09, 2017: Lundbeck reports 13% revenue growth and a doubling of EBIT in first half of 2017 79

May 10, 2017: Lundbeck: 2017 guidance raised based on strong revenue growth and improved profitability 86

Feb 08, 2017: Lundbeck continues to show solid revenue growth and strong improvement in profitability 87

Corporate Communications 88

Jul 02, 2018: H. Lundbeck Appoints Dr. Deborah Dunsire As President And CEO 88

Mar 20, 2018: Lundbeck held its Annual General Meeting on 20 March 2018 at the company's registered office 89

Oct 30, 2017: Changes to Lundbeck's Executive Management 90

Sep 11, 2017: Changes in Executive Management in Lundbeck 91

Product News 92

Dec 02, 2017: Study Evaluates Refractory Epilepsy Screening Tool for LGS (REST-LGS) 92

Aug 02, 2017: 23andMe Enrolling For First-of-its-Kind Study on Major Depressive and Bipolar Disorders 93

Apr 18, 2017: Lundbeck to Present Data on Movement Disorder and Epilepsy Therapies at AAN Annual Meeting 94

03/20/2018: Domain Therapeutics to receive up to USD 125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biotech 95

Mar 03, 2017: Bioneer: In the Forefront of Developing New Human Cell Models for Neurodegenerative Diseases 96

Clinical Trials 97

Jun 25, 2018: Lundbeck starts clinical development of potential new treatment of Parkinson's disease 97

Jul 10, 2017: Parkinson's disease: Prexton announces initiation of phase II clinical testing 98

Appendix 99

Methodology 99

About GlobalData 99

Contact Us 99

Disclaimer 99


List Of Figure

List of Figures

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

H. Lundbeck AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

H. Lundbeck AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

H. Lundbeck AS, Deals By Therapy Area, 2012 to YTD 2018 10

H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For USD 27 Million 15

Naurex Raises USD80 Million in Series C Venture Financing 17

Naurex Raises USD 25 Million In Venture Financing 19

Naurex Raises USD 38 Million In Series B Financing 21

Confo Therapeutics Enters into Agreement with H. Lundbeck 23

Cerveau Technologies Enters into Research Agreement with Lundbeck 24

H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 25

Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 26

H. Lundbeck Enters into Agreement with IBM Watson Health 27

Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 28

Ossianix Expands and Extends Research Agreement with Lundbeck 29

Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 30

Ossianix Enters Into Co-Development Agreement With Lundbeck 31

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33

Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 34

Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 35

ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 36

Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer's Disease 37

MindImmune Therapeutics Enters into Licensing Agreement with Lundbeck 38

Lundbeck Enters into Licensing Agreement with Vanderbilt University 39

Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 40

Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 41

H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 42

H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 43

H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 44

Chelsea Therapeutics Completes Public Offering Of Shares For USD 23 Million 45

Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of USD 100 Million 46

Chelsea Therapeutics Completes Public Offering Of Common Stock For USD 24 Million 47

Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For USD 100 Million 49

Lundbeck Acquires Prexton Therapeutics 51

H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 52

Lundbeck Acquires 4.6% Stake In Biotie Therapies For USD 13 Million 54

H. Lundbeck AS, Key Competitors 55

H. Lundbeck AS, Key Employees 56

H. Lundbeck AS, Subsidiaries 57

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

H. Lundbeck AS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of the central nervous system (CNS) diseases including psychiatric and neurological disorders. Its products are indicated for the treatment of diseases such as Alzheimer's disease, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington's disease, among others. The company operates production facilities in Denmark, France, Italy and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies and hospitals in Europe, the US and other countries. Lundbeck is headquartered in Valby, Denmark.

H. Lundbeck AS (LUN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

H. Lundbeck AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For USD 27 Million 15

Venture Financing 17

Naurex Raises USD80 Million in Series C Venture Financing 17

Naurex Raises USD 25 Million In Venture Financing 19

Naurex Raises USD 38 Million In Series B Financing 21

Partnerships 23

Confo Therapeutics Enters into Agreement with H. Lundbeck 23

Cerveau Technologies Enters into Research Agreement with Lundbeck 24

H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 25

Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 26

H. Lundbeck Enters into Agreement with IBM Watson Health 27

Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 28

Ossianix Expands and Extends Research Agreement with Lundbeck 29

Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 30

Ossianix Enters Into Co-Development Agreement With Lundbeck 31

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33

Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 34

Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 35

ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 36

Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer's Disease 37

Licensing Agreements 38

MindImmune Therapeutics Enters into Licensing Agreement with Lundbeck 38

Lundbeck Enters into Licensing Agreement with Vanderbilt University 39

Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 40

Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 41

H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 42

Equity Offering 43

H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 43

H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 44

Chelsea Therapeutics Completes Public Offering Of Shares For USD 23 Million 45

Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of USD 100 Million 46

Chelsea Therapeutics Completes Public Offering Of Common Stock For USD 24 Million 47

Asset Transactions 49

Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For USD 100 Million 49

Acquisition 51

Lundbeck Acquires Prexton Therapeutics 51

H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 52

Lundbeck Acquires 4.6% Stake In Biotie Therapies For USD 13 Million 54

H. Lundbeck AS-Key Competitors 55

H. Lundbeck AS-Key Employees 56

H. Lundbeck AS-Locations And Subsidiaries 57

Head Office 57

Other Locations & Subsidiaries 57

Recent Developments 61

Financial Announcements 61

Nov 07, 2018: Lundbeck realized 12% growth in revenue and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised 61

Aug 08, 2018: Lundbeck realized 14% growth in revenue (local currencies) and 83% growth in EPS 62

May 08, 2018: Lundbeck realized 14% growth in revenue (local currency) and 103% growth in EPS 76

Feb 07, 2018: Lundbeck delivers its best financial results following 10% revenue growth and 117% growth in net profit 77

Nov 08, 2017: Lundbeck increased operating profit (EBIT) with 126% and EPS by 182% in the first nine months of 2017 78

Aug 09, 2017: Lundbeck reports 13% revenue growth and a doubling of EBIT in first half of 2017 79

May 10, 2017: Lundbeck: 2017 guidance raised based on strong revenue growth and improved profitability 86

Feb 08, 2017: Lundbeck continues to show solid revenue growth and strong improvement in profitability 87

Corporate Communications 88

Jul 02, 2018: H. Lundbeck Appoints Dr. Deborah Dunsire As President And CEO 88

Mar 20, 2018: Lundbeck held its Annual General Meeting on 20 March 2018 at the company's registered office 89

Oct 30, 2017: Changes to Lundbeck's Executive Management 90

Sep 11, 2017: Changes in Executive Management in Lundbeck 91

Product News 92

Dec 02, 2017: Study Evaluates Refractory Epilepsy Screening Tool for LGS (REST-LGS) 92

Aug 02, 2017: 23andMe Enrolling For First-of-its-Kind Study on Major Depressive and Bipolar Disorders 93

Apr 18, 2017: Lundbeck to Present Data on Movement Disorder and Epilepsy Therapies at AAN Annual Meeting 94

03/20/2018: Domain Therapeutics to receive up to USD 125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biotech 95

Mar 03, 2017: Bioneer: In the Forefront of Developing New Human Cell Models for Neurodegenerative Diseases 96

Clinical Trials 97

Jun 25, 2018: Lundbeck starts clinical development of potential new treatment of Parkinson's disease 97

Jul 10, 2017: Parkinson's disease: Prexton announces initiation of phase II clinical testing 98

Appendix 99

Methodology 99

About GlobalData 99

Contact Us 99

Disclaimer 99


List Of Figure

List of Figures

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

H. Lundbeck AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

H. Lundbeck AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

H. Lundbeck AS, Deals By Therapy Area, 2012 to YTD 2018 10

H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For USD 27 Million 15

Naurex Raises USD80 Million in Series C Venture Financing 17

Naurex Raises USD 25 Million In Venture Financing 19

Naurex Raises USD 38 Million In Series B Financing 21

Confo Therapeutics Enters into Agreement with H. Lundbeck 23

Cerveau Technologies Enters into Research Agreement with Lundbeck 24

H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 25

Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 26

H. Lundbeck Enters into Agreement with IBM Watson Health 27

Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 28

Ossianix Expands and Extends Research Agreement with Lundbeck 29

Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 30

Ossianix Enters Into Co-Development Agreement With Lundbeck 31

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33

Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 34

Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 35

ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 36

Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer's Disease 37

MindImmune Therapeutics Enters into Licensing Agreement with Lundbeck 38

Lundbeck Enters into Licensing Agreement with Vanderbilt University 39

Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 40

Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 41

H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 42

H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 43

H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 44

Chelsea Therapeutics Completes Public Offering Of Shares For USD 23 Million 45

Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of USD 100 Million 46

Chelsea Therapeutics Completes Public Offering Of Common Stock For USD 24 Million 47

Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For USD 100 Million 49

Lundbeck Acquires Prexton Therapeutics 51

H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 52

Lundbeck Acquires 4.6% Stake In Biotie Therapies For USD 13 Million 54

H. Lundbeck AS, Key Competitors 55

H. Lundbeck AS, Key Employees 56

H. Lundbeck AS, Subsidiaries 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

H. Lundbeck AS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.